Sažetak
Uvod/Cilj. Do sada nije bilo dostupnih publikovanih rezultata o upotrebi dugodelujućeg preparata paliperidon palmitata (PP) kod bolesnika sa shizofrenijom, lečenih u svakodnevnoj kliničkoj praksi u Republici Srbiji. Cilj rada bio je da se ispita stopa hospitalizacije bolesnika sa shizofrenijom pre i nakon uključivanja jednomesečnog dugodelujućeg injekcionog PP, kao i komplijantnost bolesnika lečenih tim lekom. Metode. Retrospektivnom studijom preseka ispitivana je stopa hospitalizacije kod 113 bolesnika sa dijagnozom shizofrenije, u periodu od 12 meseci pre uključivanja jednomesečnog dugodelujućeg injekcionog PP i 12 meseci nakon toga. U studiju su bili uključeni bolesnici starosti od 18 do 66 godina. Rezultati. Prosečna starost ispitanih bolesnika bila je 38,36 ± 11,62 godina. Među njima je 77 (68,1%) bilo muškog pola, a 36 (31,9%) ženskog pola. Od 113 bolesnika kojima je uključen PP, 78 (69,03%) bolesnika bilo je na monoterapiji, dok je 35 (30,97%) imalo dodatnu terapiju jednim oralnim antipsihotikom (risperidon, olanzapin, aripiprazol ili klozapin). Od ukupno 113 bolesnika, njih 68 (60,18%) nije bilo hospitalizovano, dok je 45 (39,82%) bolesnika bilo hospitalizovano u periodu od 12 meseci pre uključivanja jednomesečnog dugodelujućeg injekcionog PP. S obzirom na to da je od ukupno 113 bolesnika 8 isključeno sa terapije usled neželjenog događaja ili sopstvene odluke u periodu nakon uključivanja PP, analiza stope hospitalizacije posle uključivanja PP izvršena je u grupi od 105 bolesnika, od kojih je njih 9 (8,57%) bilo hospitalizovano u periodu posle uključivanja PP, a 96 (91,43%) nije. Zaključak. Naši rezultati pokazuju visoku komplijantnost bolesnika u lečenju jednomesečnim injekcionim PP i pozitivan uticaj tog leka na nisku stopu hospitalizacije bolesnika sa shizofrenijom, tokom perioda praćenja od 12 meseci. S obzirom na dostupnost PP u Republici Srbiji, ovakvi rezultati su ohrabrenje za njegovu upotrebu, kao važne terapijske opcije za lečenje bolesnika sa shizofrenijom.
Ključne reči
Array
Array
Array
Array
Array
Array
Array
Reference
1. Brohan E, Elgie R, Sartorius N, Thornicroft G; GAMIAN-Europe Study Group. Self-stigma, empowerment and perceived discrimination among people with schizophrenia in 14 European countries: the GAMIAN-Europe study. Schizophr Res 2010; 122(1–3): 232–8.
2. Republic expert committee for the development and implementation of good clinical practice guidelines. National Guide to Good Clinical Practice for diagnosing and treating schizophrenia. Belgrade: Ministry of Health of the Republic of Serbia; 2013. (Serbian)
3. Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry 2020; 177(9): 868–72.
4. Ostuzzi G, Bertolini F, Tedeschi F, Vita G, Brambilla P, Del Fabro L, et al. Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. World Psychiatry 2022; 21(2): 295–307.
5. Lin D, Joshi K, Keenan A, Shepherd J, Bailey H, Berry M, et al. Associations Between Relapses and Psychosocial Outcomes in Patients With Schizophrenia in Real-World Settings in the United States. Front Psychiatry 2021; 12: 695672.
6. Pennington M, McCrone P. The Cost of Relapse in Schizophrenia. Pharmacoeconomics 2017; 35(9): 921–36.
7. Lysaker PH, Pattison ML, Leonhardt BL, Phelps S, Vohs JL. Insight in schizophrenia spectrum disorders: relationship with behavior, mood and perceived quality of life, underlying causes and emerging treatments. World Psychiatry 2018; 17(1): 12–23.
8. Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol 2014; 4(5): 198–219.
9. Medicines and Medical Devices Agency of Serbia. Search of medicines and medical devices [Internet]. Republic of Serbia: Medicines and Medical Devices Agency of Serbia; [cited 2022 Dec 11]. Available from: https://www.alims.gov.rs/humani-lekovi/pretrazivanje-humanih-lekova/
10. U.S. Food and Drug Administration. Drug Approvals and Databases [Internet]. USA: Food and Drug Administration; [cited 2022 Dec 11]. Available from: https://www.fda.gov/drugs/
development-approval-process-drugs/drug-approvals-and-data
bases
11. European Medicines Agency. Medicines [Internet]. European Union: The European Medicines Agency; [cited 2022 Dec 11]. Available from: https://www.ema.europa.eu/en
/medicines
12. Kane JM, McEvoy JP, Correll CU, Llorca PM. Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia. CNS Drugs 2021; 35(11): 1189–205.
13. Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, et al. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence. J Clin Psychiatry 2016; 77(Suppl 3): 1–24.
14. Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry 2021; 8(5): 387–404.
15. Leucht S, Samara M, Heres S, Davis JM. Dose Equivalents for Antipsychotic Drugs: The DDD Method. Schizophr Bull 2016; 42(Suppl 1): S90–4.
16. Gutiérrez-Rojas L, Sánchez-Alonso S, García Dorado M, López Rengel PM. Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain. CNS Drugs 2022; 36(5): 517–27.
17. Marques-Teixeira J, Amorim G, Pires AC. Results from PSIPROSPER: A multicenter retrospective study to analyze the impact of treatment with paliperidone palmitate 1-month on clinical outcomes and hospital resource utilization in adult patients with schizophrenia in Portugal. Front Psychiatry 2022; 13: 992256.
18. Devrimci-Ozguven H, Atmaca M, Baran Z, Cengisiz C, Çinar C, Erol A, et al. Efficacy and Safety of Paliperidone Palmitate Treatment in Patients With Schizophrenia: A Real-World Multicenter, Retrospective, Mirror-Image Study. J Clin Psychopharmacol 2019; 39(6): 604–10.
19. Fernández-Miranda JJ, Díaz-Fernández S. Tolerability of effective high doses of paliperidone palmitate in patients with severe resistant schizophrenia. Int Clin Psychopharmacol 2017; 32(1): 6–12.